Innovation in the production process of veterinary drugs against leptospirosis and borreliosis (Q9935): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item)
Property / instance of
 
Property / instance of: Kohesio project / rank
 
Normal rank
Property / financed by
 
Property / financed by: European Union / rank
 
Normal rank
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
 
Normal rank

Revision as of 16:21, 3 March 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Innovation in the production process of veterinary drugs against leptospirosis and borreliosis
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    7,500,000.0 Czech koruna
    0 references
    300,000.0 Euro
    10 January 2020
    0 references
    30,000,000.0 Czech koruna
    0 references
    1,200,000.0 Euro
    10 January 2020
    0 references
    25 percent
    0 references
    19 November 2015
    0 references
    23 August 2018
    0 references
    1 October 2018
    0 references
    Bioveta, a.s.
    0 references
    0 references

    49°18'9.65"N, 17°4'54.52"E
    0 references

    49°17'53.88"N, 17°6'21.31"E
    0 references
    68323
    0 references
    Předmětem projektu je inovace procesu výroby a kultivace vakcín proti leptospiróze a borelióze založená na pomnožení spirochet fermentační kultivací v průmyslovém bioreaktoru. Inovace procesu bude realizována formou zavedení nové technologie výroby antigenů. Inovace se týká celé řady přípravků (např. Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofel B, Biocan B, Borrelym). V rámci projektu bude pořízena technologie pro nový způsob výroby, a to bioreaktory, formulační kotel a ultrafiltr. a. (Czech)
    0 references
    The purpose of the project is to innovate the process of producing and cultivating vaccines against leptospirosis and borreliosis based on the multiplication of spirochet fermentation culture in an industrial bioreactor. The process of innovation will be realised through the introduction of new technology for producing antigens. Innovation covers a wide range of products (e.g.: Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofl B, Biocan B, Borrely). The project will produce a technology for a new method of production, namely bioreactors, a co-formulant and an ultra filteum. (English)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/15_014/0004382
    0 references